Table 3.
Lymphocyte subset counts in SCOT participants and healthy controls (cells per microliter)
| Lymphocyte subset | Median (10th–90th percentiles) |
|||
|---|---|---|---|---|
| Healthy controls (n = 123) | SCOT participants |
|||
| All subjects (n = 71) | Immunosuppressive naïve (n = 14) | Immunosuppressive exposed (n = 57) | ||
| T cells | 1447 (799–2247) | 1226 (513–2386) | 1181 (719–2504) | 1226 (452–2386) |
| CD4 T cells | 935 (503–1544 | 836 (335–1806) | 731 (444–1924) | 843 (334–1806) |
| CD8 T cells | 395 (199–735) | 261 (100–667)*** | 347 (232–556) | 247 (99–721)*** |
| Naïve CD4 T cells | 88 (26–273) | 187 (38–390)*** | 231 (38–375)* | 173 (24–467)*** |
| Central memory CD4 T cells | 376 (199–683) | 244 (82–518)*** | 227 (66–717) | 252 (82–518)*** |
| Effector memory CD4 Cells | 16 (6–42) | 21 (8–91)** | 31 (4–94) | 20 (9–91)* |
| Naïve CD8 T cells | 35 (7–119) | 36 (5–119) | 81 (6–127) | 27 (4–119) |
| Central memory CD8 T cells | 108 (49–246) | 15 (2–65)*** | 13 (4–49)*** | 15 (2–70)*** |
| Effector CD8 T cells | 5 (1–19) | 26 (6–90)*** | 29 (9–106)*** | 24 (6–90)*** |
| Activated T cells | 99 (40–256) | 27 (7–287)*** | 57 (13–402) | 25 (6–259)*** |
| Activated CD4 T cells | 53 (20–138) | 9 (2–148)*** | 16 (4–296) | 9 (2–139)*** |
| γ/δ T cells | 39 (13–97) | 22 (5–66)*** | 41 (4–94) | 20 (5–63)*** |
| Induced Th1 CD4 T cells | 205 (64–543) | 230 (28–667) | 269 (24–1071) | 217 (28–568) |
| Induced Th2 CD4 T cells | 13 (2–49) | 36 (4–95)*** | 31 (0–131) | 36 (6–95)*** |
| Th2:Th1 CD4 cells ratio | 0.051 (0.018–0.150) | 0.146 (0.033–0.724)*** | 0.146 (0.000–0.209) | 0.153 (0.035–0.746)*** |
| Induced Tc1 CD8 T cells | 249 (79–585) | 209 (47–633) | 268 (22–633) | 182 (47–702) |
| Induced Tc2 CD8 T cells | 2 (1–13) | 4 (1–21)* | 4 (0–10) | 4 (1–25)* |
| Tc2:Tc1 CD8 cells ratio | 0.010 (0.002–0.056) | 0.021 (0.004–0.213)** | 0.015 (0.000–0.108)* | 0.021 (0.004–0.254)*** |
| B cells | 197 (87–449) | 161 (42–430) | 208 (84–320) | 159 (39–458) |
| Naïve B cells | 151 (62–351) | 148 (37–375) | 183 (54–291) | 141 (33–425) |
| Non-switched memory B cells | 13 (5–29) | 6 (1–18)*** | 7 (1–18)* | 6 (1–22)*** |
| Switched memory B cells | 25 (9–57) | 6 (2–17)*** | 10 (4–17)*** | 5 (2–22)*** |
| Myeloid dendritic cells/precursors | 43 (24–88) | 18 (8–49)*** | 17 (9–70)* | 19 (8–42)*** |
| Plasmacytoid dendritic cells/precursors | 5 (2–9) | 3 (0–7)*** | 2 (0–6)* | 3 (0–9)** |
| CD3+CD4+CD25+Fox P3+ (Treg) | 37 (7–134) | 3 (0–17)*** | 4 (0–13)*** | 2 (0–17)*** |
| CD3+CD4+CD25+FoxP3+CD127− (Treg) | 34 (6–125) | 2 (0–15)*** | 4 (0–10)*** | 2 (0–15)*** |
IS: immunosuppressive.
*P < 0.05, **P < 0.01 and ***P < 0.001, compared with healthy controls. No significant differences were observed between immunosuppressive-exposed and naïve patients.